InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
68,706.58
(
0.26%
)
Post# of 2983
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 30
Posts 4098
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: None

Monday, 10/17/2022 12:28:00 PM

Monday, October 17, 2022 12:28:00 PM

Post# of 2983
ENTA doses the first person in a phase I safety study of their new RSV L-protein inhibitor EDP-323.

https://finance.yahoo.com/news/enanta-pharmaceuticals-doses-first-subject-110000022.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ENTA News
More ENTA News
InvestorsHub NewsWire

Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM

Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM

"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM

North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

Start posting your company's news
Only $200 per official company press release!